何玲玲 程淑芬

摘 要：目的 观察冠心病心力衰竭患者施予曲美他嗪与琥珀酸美托洛尔联合治疗的效果。方法 将本院收治的120例冠心病心力衰竭患者随机分为A组与B组，各60例。A组行常规治疗，B组在A组基础上施予曲美他嗪与琥珀酸美托洛尔联合治疗，比较两组的临床疗效及治疗前后患者的心肌功能情况。结果 治疗后B组患者LVEDD、LVESD、DBF、SBF低于A组，LVEF高于A组，差异有统计学意义（P<0.05）；A组总有效率为81.67%，低于B组的96.67%，差异有统计学意义（P<0.05）。结论 曲美他嗪与琥珀酸美托洛尔联合治疗冠心病心力衰竭，临床效果显著，可有效改善患者心肌功能。

关键词：冠心病；心力衰竭；曲美他嗪；琥珀酸美托洛尔

中图分类号：R541 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.13.042

文章编号：1006-1959（2018）13-0142-02

Abstract：Objective To observe the effect of combined treatment with trimetazidine and metoprolol succinate in patients with coronary heart disease and heart failure.Methods 120 patients with coronary heart disease admitted to our hospital were randomly divided into group A and group B，60 cases in each group.Group A was treated routinely.Group B was treated with combination of trimetazidine and metoprolol succinate on the basis of group A.The clinical efficacy of the two groups and the myocardial function of the patients before and after treatment were compared.Results After treatment，LVEDD，LVESD，DBF and SBF were lower in group B than in group A，and LVEF was higher than that in A group，the difference was statistically significant（P<0.05），and the total effective rate of group A was 81.67%，lower than that of group B 96.67%，and the difference was statistically significant（P<0.05）.Conclusion Trimetazidine combined with metoprolol succinate is effective in treating coronary heart disease with heart failure.It can effectively improve myocardial function in patients with coronary heart disease.

Key words：Coronary heart disease；Heart failure；Trimetazidine；Metoprolol succinate

冠心病（coronary heart disease）作為心内科常见疾病之一，其临床发病率呈现出逐年增加趋势，是造成心肌缺氧缺血或心肌坏死的重要原因[1]。冠心病患者病情进展后，往往会伴随心力衰竭现象，需及时开展有效治疗，否则病情持续加重后可能危及患者的生命安全。曲美他嗪作为一种抗心肌缺血药物，在冠心病患者治疗中应用广泛；而琥珀酸美托洛尔属于β1受体拮剂，也是治疗冠心病的重要药物[2]。为了进一步研究曲美他嗪与琥珀酸美托洛尔联合治疗冠心病心力衰竭的疗效，选取本院收治的120例冠心病心力衰竭患者展开分析，现报告如下。

1资料与方法

1.1一般资料 选取2015年1月～2016年1月解放军第四五二医院收治的冠心病心力衰竭患者120例，本研究通过医院伦理会批准。纳入标准：①所有患者入院后均通过冠状动脉造影、血管内成像检查确诊；②结果与第六版《内科学》[3]冠心病心力衰竭诊断标准相符；③患者伴有乏力、呼吸困难以及下肢水肿等表现；……